Different inhibitors for the same target in metastatic luminal breast cancer: is there any difference?

Abstract

AIM:

To determine which of the CDK4/6 inhibitors is the optimal treatment in metastatic luminal breast cancer.

MATERIALS & METHODS:

A network meta-analysis using the frequentist approach and generalized pairwise modeling was computed.

RESULTS:

The associations of aromatase inhibitor with ribociclib, palbociclib and abemaciclib were similar in efficacy. Palbociclib-based regimen was associated with significantly lower treatment discontinuation rates compared with the other approved drugs in this indication.

CONCLUSION:

In the absence of direct comparative evidence, the results of this network meta-analysis represent the best available evidence for decision making in the first-line treatment of metastatic luminal breast cancer.

• Authors: Elie El Rassy, Ziad Bakouny, Tarek Assi, Joseph Kattan
• Journal: Future oncology (London, England) (Future Oncol) Vol. 14 Issue 9 Pg. 891-895 (Apr 2018) ISSN: 1744-8301 [Electronic] England
• PMID: 29527939 (Publication Type: Journal Article, Meta-Analysis)

Chemical References

• Aminopyridines
• Benzimidazoles
• Piperazines
• Purines
• Pyridines
• abemaciclib
• Cyclin-Dependent Kinase 4
• Cyclin-Dependent Kinase 6
• palbociclib
• ribociclib

Topics

• Aminopyridines (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Benzimidazoles (therapeutic use)
• Breast Neoplasms (drug therapy, genetics, pathology)
• Cell Cycle (drug effects)
• Cyclin-Dependent Kinase 4 (antagonists & inhibitors, genetics)
• Cyclin-Dependent Kinase 6 (antagonists & inhibitors, genetics)
• Female
• Humans
• Piperazines (therapeutic use)
• Purines (therapeutic use)
• Pyridines (therapeutic use)